REAL-WORLD EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN THE PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTIINSTITUTIONAL COHORT IN TAIWAN

被引：0
|
作者：
Kuo, Y. C. [1 ]
Chang, K. C. [2 ]
Chen, H. Y. [3 ]
机构：
[1] Linkou Chang Gung Mem Hosp, Taoyuan, Tao, Taiwan
[2] Chang Gung Mem Hosp, Taoyuan, Taiwan
[3] Linkou Chang Gung Mem Hosp, Dept Pharm, Taoyuan, Tao, Taiwan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD134
引用
收藏
页码：S475 / S475
页数：1
相关论文
共 50 条
  • [21] Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data
    Shimose, Shigeo
    Sugimoto, Rie
    Hiraoka, Atsushi
    Tanaka, Masatoshi
    Iwamoto, Hideki
    Tanaka, Yuki
    Tada, Fujimasa
    Ohama, Hideko
    Niizeki, Takashi
    Shirono, Tomotake
    Moriyama, Etsuko
    Noda, Yu
    Kamachi, Naoki
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    HEPATOLOGY RESEARCH, 2023, 53 (02) : 116 - 126
  • [22] ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK
    Cosgrove, David
    Tan, Amie
    Hernandez, Sairy
    Mahrus, Sami
    Osterland, Andrew
    Murphy, John
    Loaiza-Bonilla, Arturo
    HEPATOLOGY, 2022, 76 : S1308 - S1309
  • [23] Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
    Shen, Xiao
    Zhang, Jin-Xing
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Cheng, Yuan
    Zhang, Qing-Qiao
    Yin, Guo-Wen
    Zu, Qing-Quan
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1993 - 2003
  • [24] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Woo, Hyun Young
    Hwang, Sangyoun
    Heo, Jeong
    Kim, Hyung Jun
    Park, Young Joo
    Yi, Ki Youn
    Lee, Yu Rim
    Park, Soo Young
    Chung, Woo Jin
    Jang, Byoung-Kuk
    Tak, Won Young
    HEPATOLOGY, 2023, 78 : S1880 - S1881
  • [25] EXPLORATORY EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA ( HCC) BEYOND RADIOLOGICAL PROGRESSION: A REAL- WORLD, MULTICENTER COHORT STUDY
    Tabuchi, Takaya
    Taniki, Nobuhito
    Kasuga, Ryosuke
    Chu, Po-sung
    Nakadai, Yukie
    Kondo, Mayuko
    Noguchi, Fumie
    Morikawa, Rei
    Shiba, Shunsuke
    Tahara, Toshiyuki
    Komatsu, Hirokazu
    Fujita, Yuriko
    Kaneko, Fumihiko
    Hoshi, Hitomi
    Ojiro, Keisuke
    Hosoda, Yasuo
    Yamaguchi, Akihiro
    Fukuhara, Seiichiro
    Okamura, Yukishige
    Kanamori, Hideaki
    Kanai, Takanori
    Nakamoto, Nobuhiro
    HEPATOLOGY, 2023, 78 : S1841 - S1842
  • [26] ANALYSIS OF FACTORS PREDICTING THE REAL-WORLD EFFICACY OF ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Ha, Chang Won
    Paik, Yong-Han
    Song, Byeong Geun
    HEPATOLOGY, 2024, 80
  • [27] Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
    Song, Byeong Geun
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Yong-Han
    GUT AND LIVER, 2024, 18 (04) : 709 - 718
  • [28] Potential faesability of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis
    Stefanini, Benedetta
    Bucci, Laura
    Santi, Valentina
    Reggidori, Nicola
    Rampoldi, Davide
    Lani, Lorenzo
    Trevisani, Franco
    JOURNAL OF HEPATOLOGY, 2022, 77 : S382 - S383
  • [29] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Sae Yumita
    Sadahisa Ogasawara
    Miyuki Nakagawa
    Susumu Maruta
    Tomomi Okubo
    Norio Itokawa
    Yotaro Iino
    Masamichi Obu
    Yuki Haga
    Atsuyoshi Seki
    Tadayoshi Kogure
    Takamasa Ishino
    Keita Ogawa
    Kisako Fujiwara
    Terunao Iwanaga
    Naoto Fujita
    Takafumi Sakuma
    Ryuta Kojima
    Hiroaki Kanzaki
    Keisuke Koroki
    Masanori Inoue
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Naoya Kanogawa
    Tomoko Saito
    Takayuki Kondo
    Ryo Nakagawa
    Shingo Nakamoto
    Ryosuke Muroyama
    Tetsuhiro Chiba
    Ei Itobayashi
    Masanori Atsukawa
    Yoshihiro Koma
    Ryosaku Azemoto
    Kenji Ito
    Hideaki Mizumoto
    Jun Kato
    Naoya Kato
    BMC Gastroenterology, 23
  • [30] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Yumita, Sae
    Ogasawara, Sadahisa
    Nakagawa, Miyuki
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kogure, Tadayoshi
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Inoue, Masanori
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Kato, Jun
    Kato, Naoya
    BMC GASTROENTEROLOGY, 2023, 23 (01)
12345